Merck beats estimates, lifts profit outlook on Keytruda strength
CNBC · RSS · · AI-summarised by FinFlash
Merck topped quarterly estimates and raised its profit outlook, helped by stronger-than-expected sales of its immunotherapy Keytruda, including a newer injectable form of the drug. The results point to resilient demand across the company's cancer franchise as it works to extend Keytruda's lifecycle. For investors, the raised guidance signals management expects earnings momentum to continue.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.